Nearly 40% of women with a notoriously difficult to treat, triple-negative breast cancer diagnosis had their cancer shrink or go away entirely with a new immunotherapy triple-drug treatment developed by researchers at Baltimore-based Johns Hopkins Medicine.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
